Cargando…
Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure
BACKGROUND: The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure. METHODS: Consecutive cases of acute phacomorphic ang...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544332/ https://www.ncbi.nlm.nih.gov/pubmed/23326185 http://dx.doi.org/10.2147/OPTH.S39503 |
_version_ | 1782255774409424896 |
---|---|
author | Lee, Jacky WY Lai, Jimmy SM Yick, Doris WF Yuen, Can YF |
author_facet | Lee, Jacky WY Lai, Jimmy SM Yick, Doris WF Yuen, Can YF |
author_sort | Lee, Jacky WY |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure. METHODS: Consecutive cases of acute phacomorphic angle closure were randomized to receive ALPI and an intravenous or oral carbonic anhydrase inhibitor as initial treatment. Intravenous mannitol was administered for presenting IOP > 60 mmHg or IOP > 40 mmHg 2 hours posttreatment in both arms. RESULTS: Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty percent in the medical group and none in the ALPI group required intravenous mannitol. The ALPI group took less time to achieve IOP < 25 mmHg (18.8 ± 7.5 minutes versus 115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction within 30 minutes (69.8% ± 7.7% versus 40.9 ± 23.9%, P = 0.03, t-test); and had a consistently smaller post-attack cup to disc ratio (0.50 ± 0.02 versus 0.60 ± 0.20, P = 0.002, F test). CONCLUSION: ALPI offers greater safety, consistency, and efficacy than systemic IOP-lowering medications as initial treatment for phacomorphic angle closure. |
format | Online Article Text |
id | pubmed-3544332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35443322013-01-16 Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure Lee, Jacky WY Lai, Jimmy SM Yick, Doris WF Yuen, Can YF Clin Ophthalmol Original Research BACKGROUND: The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure. METHODS: Consecutive cases of acute phacomorphic angle closure were randomized to receive ALPI and an intravenous or oral carbonic anhydrase inhibitor as initial treatment. Intravenous mannitol was administered for presenting IOP > 60 mmHg or IOP > 40 mmHg 2 hours posttreatment in both arms. RESULTS: Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty percent in the medical group and none in the ALPI group required intravenous mannitol. The ALPI group took less time to achieve IOP < 25 mmHg (18.8 ± 7.5 minutes versus 115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction within 30 minutes (69.8% ± 7.7% versus 40.9 ± 23.9%, P = 0.03, t-test); and had a consistently smaller post-attack cup to disc ratio (0.50 ± 0.02 versus 0.60 ± 0.20, P = 0.002, F test). CONCLUSION: ALPI offers greater safety, consistency, and efficacy than systemic IOP-lowering medications as initial treatment for phacomorphic angle closure. Dove Medical Press 2013 2013-01-09 /pmc/articles/PMC3544332/ /pubmed/23326185 http://dx.doi.org/10.2147/OPTH.S39503 Text en © 2013 Lee et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Lee, Jacky WY Lai, Jimmy SM Yick, Doris WF Yuen, Can YF Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
title | Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
title_full | Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
title_fullStr | Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
title_full_unstemmed | Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
title_short | Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
title_sort | argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544332/ https://www.ncbi.nlm.nih.gov/pubmed/23326185 http://dx.doi.org/10.2147/OPTH.S39503 |
work_keys_str_mv | AT leejackywy argonlaserperipheraliridoplastyversussystemicintraocularpressureloweringmedicationsasimmediatemanagementforacutephacomorphicangleclosure AT laijimmysm argonlaserperipheraliridoplastyversussystemicintraocularpressureloweringmedicationsasimmediatemanagementforacutephacomorphicangleclosure AT yickdoriswf argonlaserperipheraliridoplastyversussystemicintraocularpressureloweringmedicationsasimmediatemanagementforacutephacomorphicangleclosure AT yuencanyf argonlaserperipheraliridoplastyversussystemicintraocularpressureloweringmedicationsasimmediatemanagementforacutephacomorphicangleclosure |